Neuropsychiatric manifestations after mefloquine therapy for Plasmodium falciparum malaria: comparing a retrospective and a prospective study
| Autor: | Ib C. Bygbjerg, Peter C Gøtzsche, Anita M. Rønn, J Rønne-Rasmussen |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Neuropsychiatry Antimalarials Bias Surveys and Questionnaires Prevalence Adverse Drug Reaction Reporting Systems Humans Medicine Prospective Studies Malaria Falciparum Prospective cohort study Psychiatry Depression (differential diagnoses) Retrospective Studies business.industry Mefloquine Mental Disorders Public Health Environmental and Occupational Health Toxic encephalopathy Retrospective cohort study medicine.disease Infectious Diseases Research Design Female Parasitology Nervous System Diseases medicine.symptom business Mania Malaria medicine.drug |
| Zdroj: | Tropical Medicine and International Health. 3:83-88 |
| ISSN: | 1365-3156 1360-2276 |
| Popis: | Mefloquine is widely used for the treatment of patients with chloroquine-resistant Plasmodium falciparum malaria. A 1987 report of possible mefloquine-induced toxic encephalopathy prompted an investigation by the manufacturer and the World Health Organization (WHO) of adverse psychiatric events associated with use of this antimalarial. Interim guidelines were issued by WHO in 1989 and a more systematic surveillance was initiated. Subsequent studies identified neuropsychiatric side effects in 1/159-1/1217 treated individuals. The authors of this paper launched a 3-year prospective study (1990-93) of 54 malaria patients treated with mefloquine at a medical center in Copenhagen Denmark and compared its results with those of their earlier (1982-88) retrospective study of 81 malaria patients treated at the same facility. No cases of adverse neurologic or neuropsychiatric sequelae were recorded in the retrospective study which did not specifically probe about such effects. In the prospective study which did include questions on this outcome 15 patients (28%) had one or more mild or moderate neuropsychiatric complaint (e.g. hallucinations nightmares depression anxiety sleeplessness and mania). Non-neuropsychiatric adverse reactions occurred in 78 patients (96%) in the retrospective study and 44 (81%) in the prospective study. These findings point out that studies conducted under virtually the same conditions may produce discrepant results depending on what is probed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text